This discussion between Drs. Diana Castro and Jonathan Strober focuses on the clinical utility of patient stratification and antibody profiling in generalized myasthenia gravis (gMG). The conversation addresses how age of onset, antibody status (acetylcholine receptor, MuSK, LRP4), and comorbidities can influence diagnosis and management plans. The speakers highlight the limitations of current pediatric assessment tools and the implications of antibody status for access to targeted therapies. Practical considerations for repeat testing, use of modified clinical scales, and individualized communication strategies with pediatric patients and families are also examined, emphasizing the nuanced approach required in younger populations.
=